This desk prices what an individual pays. It is worth occasionally looking at what a whole country pays, because the same ratio shows up: one sixth of the prescriptions, two fifths of the money [1]. That gap between share of use and share of spend is what a premium drug looks like on a budget line — the arithmetic behind whether a GLP-1 is worth its price, scaled up.
Between 2010 and 2024, total non-insulin diabetes drug consumption in Croatia more than doubled. Within that, GLP-1 drugs went from nothing to 15.99 defined daily doses per 1,000 inhabitants per day, and to 16.1% of prescriptions in the category. Their share of category spending reached 42.7%, or €42.07 million in a single year. Set the two shares side by side — 16.1% vs 42.7% — and the premium is the whole gap. Semaglutide led on both counts, followed by dulaglutide and liraglutide.
That reimbursement boundary is the practical finding for a buyer. In a system where the diabetes indication is covered and the obesity indication is not, the same molecule has two completely different prices depending on which line of a form is ticked. That is not a Croatian quirk. It is the structure of most coverage everywhere, including the US plans this desk tracks in what insurance actually covers.
Two limits on how far this travels. It is one country of about four million people with its own reimbursement rules and its own negotiated prices, so the euro figure means nothing anywhere else. And the prescription-to-spending ratio, while striking, reflects those negotiated prices too; a country paying differently would show a different gap.
What does transfer is the shape. A drug class that reaches a sixth of prescriptions and takes over two fifths of the budget will attract exactly the cost-containment attention it is attracting, and coverage rules are the lever systems reach for first. For a cash buyer that matters directly, because every tightening pushes more people onto the self-pay prices this desk publishes — the dynamic set out in what employer coverage really reaches.